Skip to main content
PolicySpeak
← All files
AG

Attomol GmbH

Company · Germany

2
positions filed
in the 326 files tracked
1
legislative file
of 326 tracked
0
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

Track Attomol in PolicySpeak: request access →

Work at Attomol GmbH? so we know who speaks for it.

Follow the file Attomol GmbH engages with

One email on Tuesdays when a new position is filed on this file, from Attomol GmbH or from anyone else on it. Only when there is something new.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Their record over time

Attomol GmbH filed 2 positions between 16 Sept 2025 and 6 Oct 2025, across 1 of the 326 legislative files tracked here.

What they argued

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 6 Oct 2025source

Sufficient views were shared on the excessive burden of complying with the IVDR. Here are a few opportunities for improvement: 1. Clear communication about what is allowed, even though it is not specifically formulated in the IVDR. This includes: (a) the non-necessary fulfilment of certain requirements (e.g.

Filed in German · English published by the European Commission

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 16 Sept 2025source

The application of the MDR/IVDR Regulations to existing products, some of which have proved for decades that they do not pose a risk to patients, is incomprehensible. Unnecessary requirements which only serve to complete paper, but do not make the products themselves safer at all. These documents are then subject to exorbitant fees from notified bodies, which are justified by the expertise of their staff.

Filed in German · English published by the European Commission

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Is this your organization?

Everything on this page comes from Attomol GmbH’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.